Recent Updates
Recently added Catalysts
CABA

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

Key Takeaway: PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Pre
Price reaction · baseline $2.18 (2022-02-25 close) · 2 other CABA headline(s) in the window, move may be shared
day 0 close
-0.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+203%
120-day peak, hindsight
Typical move
9.7%
average across 5 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
CABA-201
Phase 2 · Systemic Sclerosis

Full Press Release Details

PHILADELPHIA, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in the Neuromuscular corporate panel discussion at the Cowen Virtual 42nd Annual Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET.
A live webcast of the panel will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays of the webcast will be available on the website for 30 days.
Chief Financial Officer
Stern Investor Relations, Inc.
Last updated: Feb 28, 2022